Avelumab as neoadjuvant therapy in subjects with urothelial muscle invasive bladder cancers

Trial Profile

Avelumab as neoadjuvant therapy in subjects with urothelial muscle invasive bladder cancers

Recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Sep 2018

At a glance

  • Drugs Avelumab (Primary) ; Cisplatin; Doxorubicin; Gemcitabine; Methotrexate; Paclitaxel; Vinblastine
  • Indications Urogenital cancer
  • Focus Therapeutic Use
  • Acronyms AURA trial
  • Most Recent Events

    • 16 Mar 2018 New trial record
    • 16 Feb 2018 Trial design presented at the 2018 Genitourinary Cancers Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top